ThromboGenics submits Ocriplasmin BLA

ThromboGenics N.V. (Euronext:THR) submitted a BLA to FDA for ocriplasmin intravitreal injection to treat symptomatic vitreomacular adhesion (VMA) including macular hole. The recombinant microplasmin i...